Breaking Finance News

Concordia International Corp (NASDAQ:CXRX) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $3.55, Concordia International Corp (NASDAQ:CXRX) traded -3.27% lower on the day. With the last close down -80.55% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CXRX has recorded a 50-day average of $5.81 and a two hundred day average of $18.25. Trade Volume was down over the average, with 1,337,352 shares of CXRX changing hands under the typical 1,401,070

Zacks Investment Research has upgraded Concordia International Corp (NASDAQ:CXRX) to Hold in a statement released on 10/17/2016.

Recent Performance Chart

Concordia International Corp (NASDAQ:CXRX)

Concordia International Corp has with a one year low of $3.43 and a one year high of $44.00 and has a market capitalization of $0.

A total of 10 analysts have released a report on Concordia International Corp. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $52.01.

General Company Details For Concordia International Corp (NASDAQ:CXRX)

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *